Apollomics, Inc. (APLM)

US — Healthcare Sector
Peers: CRIS  PCSA  BCTX  HOTH  NXTC  LNAI  LIXT  RLYB  LSTA  CLSD 

Automate Your Wheel Strategy on APLM

With Tiblio's Option Bot, you can configure your own wheel strategy including APLM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol APLM
  • Rev/Share 0.1796
  • Book/Share 4.4114
  • PB 7.2494
  • Debt/Equity 0.1986
  • CurrentRatio 1.3876
  • ROIC -7.1375

 

  • MktCap 35284781.0
  • FreeCF/Share -26.0902
  • PFCF -1.2266
  • PE -0.6547
  • Debt/Assets 0.0738
  • DivYield 0
  • ROE -4.196

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
APLM, APLMW
Published: October 15, 2025 by: GlobeNewsWire
Sentiment: Neutral

FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) and request a hearing before a Nasdaq Hearings Panel to review the Staff's delisting determination.

Read More
image for news Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
APLM, APLMW
Published: October 15, 2025 by: GlobeNewsWire
Sentiment: Neutral

FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, had previously announced that it had filed an application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) and request a hearing before a Nasdaq Hearings Panel to review the Staff's delisting determination.

Read More
image for news Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

About Apollomics, Inc. (APLM)

  • IPO Date 2021-11-26
  • Website https://www.apollomicsinc.com
  • Industry Biotechnology
  • CEO Guo-Liang Yu
  • Employees 13
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.